Scarica l'app Stockscreener
23.20
3.97%
-0.96
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
NewAmsterdam Pharma: Can Obicetrapib's Data In Diabetes And Metabolic Syndrome Bring Back The Mojo? - RTTNews
NewAmsterdam Pharma Company N.V. Actuals & Estimates (HAN:KH6) - TradingView
NewAmsterdam Pharma Company N.V. (NAMS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Enterprise value of NewAmsterdam Pharma Company N.V. – HAN:KH6 - TradingView
ETFs Investing in NewAmsterdam Pharma Company N.V. Stocks - TradingView
NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease - marketscreener.com
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - The Manila Times
NewAmsterdam Pharma Company N.V. Doses First Participant In Phase 2b SPINOZA Trial Evaluating Obicetrapib In Preclinical Alzheimer?s Disease - marketscreener.com
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
Menarini and NewAmsterdam Receive EU Approval for New Drugs - Intellectia AI
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties? - insidermonkey.com
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco - BioPharma APAC
Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
NewAmsterdam Pharma wins EU approval for obicetrapib as Ubeslo and Evlarco - TradingView
EU clears NewAmsterdam Pharma (NAMS) cholesterol drug, unlocking milestone payouts with its partner - Stock Titan
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) | Corporate - EQS News
Stifel reiterates NewAmsterdam Pharma stock rating on EU approval By Investing.com - Investing.com Canada
Stifel reiterates NewAmsterdam Pharma stock rating on EU approval - Investing.com
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - PR Newswire
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
Two new cholesterol drugs get their first global approval in Europe - Stock Titan
NAMS Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesProfit Recovery Report - dars.gov.et
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run - Yahoo Finance
(NAMSW) Movement as an Input in Quant Signal Sets - Stock Traders Daily
NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock By Investing.com - za.investing.com
NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock - Investing.com
NewAmsterdam Pharma (NAMS) CEO adds to stake with fresh share purchase - Stock Titan
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com India
NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK
NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com
NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma Company N.V. - Reuters
(KH6.F) | Stock Price & Latest News - reuters.com
NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - Kalkine Media
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times
NAMSW Warrant Holds Flat at $16.51 as Consolidation Persists Below $17.34 ResistanceVolatility Term Structure - dars.gov.et
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Barchart.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):